Clinical Trial Update: Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of bevacizumab plus paclitaxel and capecitabine in triple-negative metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Triple Negative Metastatic Breast Cancer | Phase 2 | Status: TERMINATED